



Letrozole, Berberine, or Their Combination for Anovulatory Infertility in women with Polycystic Ovary Syndrome: Study Design of a Double-blind Randomized Controlled Trial

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-003934
Article Type:	Protocol
Date Submitted by the Author:	31-Aug-2013
Complete List of Authors:	Li, Yan; First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Obstetrics and Gynecology Kuang, Hongying; First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Obstetrics and Gynecology Shen, Wenjuan; First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Obstetrics and Gynecology Ma, Hongli; First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Obstetrics and Gynecology Zhang, Yuehui; First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Obstetrics and Gynecology Stener-Victorin, Elisabet; Institute of Neuroscience and Physiology, University of Gothenburg, Department of Physiology / Endocrinology Ng, Ernest; The University of Hong Kong, Obstetrics and Gynecology Liu, Jianping; Beijing University of Chinese Medicine, Centre for Evidence-Based Chinese Medicine Kuang, Haixue; Heilongjiang University of Chinese Medicine, School of Pharmacology Hou, Lihui; First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Obstetrics and Gynecology Xiao, Wu; First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Obstetrics and Gynecology
Primary Subject Heading:	Reproductive medicine
Secondary Subject Heading:	Diabetes and endocrinology, Complementary medicine, Reproductive medicine
Keywords:	REPRODUCTIVE MEDICINE, Protocols & guidelines < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Subfertility < GYNAECOLOGY, Herbal medicine < THERAPEUTICS, Clinical trials < THERAPEUTICS

Letrozole, Berberine, or Their Combination for Anovulatory Infertility in women with Polycystic Ovary Syndrome: Study Design of a Double-blind Randomized Controlled Trial

Yan Li,¹ Hongying Kuang,¹ Wenjuan Shen,¹ Hongli Ma,¹ Yuehui Zhang,¹ Elisabet Stener-Victorin,² Ernest Hung Yu Ng,³ Jianping Liu,⁴ Haixue Kuang⁵, Lihui Hou,^{1*} and Xiaoke Wu^{1*}

Abstract

Introduction: Letrozole is being used as an alternative to clomiphene citrate in women with polycystic ovary syndrome (PCOS) requiring ovulation induction. Berberine, a major active component of Chinese herbal medicine *rhizomacoptidis*, has been used to improve insulin resistance to facilitate ovulation induction in women with PCOS but there is no study reporting the live birth or its potential as a complementary treatment to letrozole. We here aim to determine the efficacy of letrozole with or without berberine in achieving live births among 660 infertile women with PCOS in Mainland China.

Methods and analysis: This study is a multicenter randomized, double blind trial. The randomization scheme is coordinated through the central mechanism and stratified by the participating site. Participants are randomized into one of three treatment arms: A) letrozole and berberine, B) letrozole and berberine placebo, or C) letrozole placebo and berberine. Berberine is administered three times a day (1.5g/day) for up to 24 weeks, starting on day 1 after a spontaneous period or a withdrawal bleeding. Either letrozole or letrozole placebo 2.5 mg is given daily from day 3 to day 7 of the first 3 cycles and the dose is increased to 5mg/day in the last 3 cycles, if not pregnant. The primary hypothesis is that combination of berberine and letrozole results in a significantly higher live birth rate than letrozole or berberine alone.

Ethics and dissemination: The study was approved by the ethics committee of First Affiliated Hospital of Heilongjiang University of Chinese Medicine. Study findings will be disseminated through peer-reviewed publications and conference presentations.

Trial registration: ClinicalTrials.gov identifier: NCT01619930

1. Background

Polycystic ovary syndrome (PCOS) is characterized by anovulation, hyperandrogenism and polycystic ovaries (PCO) on scanning and is the most common endocrine disorder in women of reproductive age as it affects 5-10% of premenopausal women.¹ Insulin resistance has been implicated in the pathogenesis of anovulation and infertility in PCOS and abnormalities in insulin action have been noted in a variety of reproductive tissues from women with PCOS and may explain the pleiotropic presentation and multi-organ involvement of the syndrome.²

The first line medical treatment for ovulation induction in PCOS women is clomiphene citrate (CC), which can result in an ovulation rate of 60–85% but a conception rate of only about 20%.³⁻⁶ Anti-oestrogenic effects on the endometrium and cervix mucus of CC are thought to cause the low conception rate.⁷ Also, CC may have a number of side effect including hot flushes, breast discomfort, abdominal distension, nausea, vomiting, nervousness, sleeplessness, headache, mood swings, dizziness, hair loss, and disturbed vision.⁶ Letrozole, an aromatase inhibitor, is traditionally applied for estrogen-dependent carcinoma, has been used for ovulation induction for about a decade.^{8,9} The effectiveness of letrozole versus CC for ovulation induction has been reviewed by two meta-analyses.^{10,11} In both meta-analyses that included six randomized controlled trials, it was concluded that even though letrozole was associated with a lower number of mature follicles per cycle, there was no significant difference in the ovulation rate per cycle or the pregnancy, multiple pregnancy or miscarriage rates between letrozole and CC. No difference was found in the live birth rate, although it was only assessed in one meta-analysis.¹¹

Based on the above two meta-analyses, letrozole appears to be at least as effective as CC in ovulation induction with some potential advantages over CC. Although side effects reported by patients in the group receiving CC were higher, while no complication was noted in the group receiving letrozole,¹² large sample sized clinical trials are still needed. As far as we know, two large randomized multicenter studies, PPCOSII (The Pregnancy in Polycystic

1
2
3 Ovary Syndrome II)¹³ and AMIGOS (Assessment of Multiple Intrauterine Gestations from
4 Ovarian Stimulation)¹⁴ are ongoing and can provide definitive evidence for pregnancy
5 outcome with the use of CC versus letrozole.
6
7
8

9
10
11 Insulin sensitizing agents are commonly used as adjunctive medication for women with
12 PCOS and metformin is widely chosen.¹⁵ Although a newly published meta-analysis showed
13 that there was no evidence that metformin improved live birth rates in combination with CC
14 (pooled OR 1.16, 95% CI 0.85 to 1.56, 7 trials, and 907 women), the clinical pregnancy rates
15 were higher for the combination of metformin and CC than CC alone (pooled OR 1.51, 95% CI
16 1.17 to 1.96, 11 trials, 1208 women).¹⁵ Further, metformin was associated with a higher
17 incidence of gastrointestinal disturbances than placebo (pooled OR 4.27, 95% CI 2.4 to 7.59, 5
18 trials, and 318 women), which hampered its clinical compliance with high dropout rates.¹⁶
19
20
21
22
23
24
25
26
27

28 Recent studies suggest that several Chinese herbal medicines could be beneficial as an
29 adjunct to conventional medical management of PCOS, but the evidence is limited due to
30 the poor methodology of existing trials.¹⁷ Berberine, the major active component of *rhizome*
31 *coptidis*, exists in a number of medicinal plants and displays a broad array of
32 pharmacological effects.¹⁸ In Chinese medicine, berberine has a long history for its anti-
33 diabetic effect. A recent meta-analysis compared different oral hypoglycaemics including
34 metformin, glipizide or rosiglitazone with berberine, and found no priority over glycaemic
35 control but a mild anti-dyslipidemic effect following berberine.¹⁹ The mechanism of its
36 hypolipidemic effect was studied using human hepatoma cells. Berberine acts differently
37 from that of statin drugs as it could up-regulate low-density lipoprotein receptor expression
38 independent of sterol regulatory element binding proteins, but dependent on extracellular
39 signal-regulated kinases (ERK) activation.²⁰
40
41
42
43
44
45
46
47
48
49
50

51
52 A series of basic research also implicated that berberine could have beneficial effects in
53 women with PCOS. In insulin resistant theca cells, berberine increased glucose transporter
54 (Glut)-4, decreased peroxisome proliferator-activated receptor (PPAR) - δ mRNA levels,
55
56
57
58
59
60

1
2
3 increased glucose uptake, and reduced insulin resistance.²¹⁻²³ These results indicate that
4
5 berberine can improve insulin sensitivity in insulin resistant ovary theca cells. In ovary
6
7 granulosa cell, berberine was found to reduce the ovarian estrogenic responsiveness by
8
9 their insulin sensitizing effects similar to metformin, but different from thiazolidinedione.²⁴
10
11 Berberine could also alleviate the degree of insulin resistance and the androgen synthesis in
12
13 cultured insulin resistant ovaries, indicating that berberine may have a favorable effect on
14
15 fertility in women with PCOS.²⁵
16

17
18 However, there is only one study investigating the effect of berberine in women with
19
20 PCOS.²⁶ Eighty-nine Chinese PCOS women with insulin resistance were randomized into one
21
22 of three treatment groups: berberine+ cyproterone acetate (CPA) (n=31), metformin +CPA
23
24 (n=30) and placebo +CPA (n=28) for three months. The author concluded that berberine
25
26 showed similar metabolic effects on amelioration of insulin sensitivity and reduction of
27
28 hyperandrogenemia, when compared to metformin. Berberine also appeared to have a
29
30 greater effect on the changes in body composition and dyslipidemia. That study was limited
31
32 by its small sample size, incomplete description of the methodology and use of surrogate
33
34 outcomes (anthropometric measures and hormonal and metabolic value changes). There is
35
36 also an ongoing trial (NCT01138930) testing efficacy of berberine on insulin resistance in
37
38 women with PCOS as measured by a hyperinsulinemic-euglycemic clamp. Berberine was
39
40 thought to be safe during clinical use.¹⁹ The side effects were commonly gastrointestinal
41
42 discomforts including constipation, diarrhea, nausea and abdominal distension. Constipation
43
44 was one of the most common gastrointestinal complaints, but it is predictable since
45
46 berberine had a long history used to treat diarrhea in China.
47

48
49 We aim to determine the efficacy of letrozole with or without berberine in achieving live
50
51 births among women with PCOS seeking pregnancy in China mainland. The primary
52
53 hypothesis is that combination of berberine and letrozole results in a significantly higher live
54
55 birth than letrozole or berberine alone. We report herein the study design of our ongoing
56
57 study.
58
59
60

2. Materials and methods

This is a multi-centre, randomized, double blind and controlled clinical trial. A total of 660 women with PCOS seeking pregnancy (or 220 per each treatment arm) will be enrolled at one of 18 participating sites and randomly assigned to three treatment arms.

The study was approved by the ethics committee of First Affiliated Hospital of Heilongjiang University of Chinese Medicine (2009LL-001-02). Written informed consent will be obtained from each patient prior her participation in the study. The trial is registered at clinicaltrials.gov (NCT01116167).

2.1. Primary and secondary hypotheses

The primary hypothesis is that combination of berberine and letrozole results in a significantly higher live birth than letrozole or berberine alone.

Secondary hypotheses are the adjunctive use of berberine to letrozole has an additive effect on the following:

- 1) Ovulation rate
- 2) Ongoing pregnancy rate at around gestation 8-10 weeks
- 3) Multiple pregnancy rate
- 4) Miscarriage rate: loss of an intrauterine pregnancy before 20 completed weeks of gestation.
- 5) Other pregnancy complications such as early pregnancy loss, gestational diabetes mellitus, pregnancy-induced hypertension and birth of small-for-gestational-age (SGA) babies.
- 6) Infant outcome
- 7) Changes in metabolic profile: glucose and insulin concentrations, cholesterol, triglycerides, high density lipoprotein (HDL-C) and low density lipoprotein (LDL-C)

- 8) Changes in hormonal profile: Follicle-stimulating hormone (FSH), Luteinizing hormone (LH), total testosterone (T), Sex hormone-binding globulin (SHBG) and Dehydroepiandrosterone sulfate (DHEAS)
- 9) Side effect.

2.2 Study population

Women with PCOS who desire pregnancy are eligible if they fulfill the following criteria.

2.2.1 Inclusion criteria

- 1) Age between 20 and 40 years.
- 2) Confirmed diagnosis of PCOS according to the Rotterdam 2003 criteria (2 out of 3):
 - a. Oligo- or anovulation
 - b. Clinical and/or biochemical signs of hyperandrogenism
 - c. Polycystic ovaries and exclusion of other etiologies (congenital adrenal hyperplasia, androgen-secreting tumors, Cushing's syndrome)
- 3) At least one patent tube and normal uterine cavity shown by hysterosalpingogram, HyCoSi or diagnostic laparoscopy within three years.
- 4) Sperm concentration 15×10^6 /mL and progressive motility (grades a* and b**) $\geq 40\%$.
*Grade a: rapid progressive motility (sperm moving swiftly, usually in a straight line).
**Grade b: slow or sluggish progressive motility (sperm may be less linear in their progression).
- 5) History of 1 year of infertility

2.2.2 Exclusion criteria

- 1) Use of hormonal drugs or other medications including Chinese herbal prescriptions in the past 3 months.
- 2) Patients with known severe organ dysfunction or mental illness.

- 3) Pregnancy, post-abortion or postpartum within the past 6 weeks.
- 4) Breastfeeding within the last 6 months.
- 5) Not willing to give written consent to the study.

Written informed consent will be obtained from each woman prior to the participation in this study.

2.3 Intervention

Eligible patients will be randomized into one of three arms: A) letrozole and berberine, B) letrozole and berberine placebo, C) letrozole placebo and berberine. Anovulatory patients will have a withdrawal bleed induced with a course of oral medroxyprogesterone acetate (MPA) before the initiation of study medication. Each subject will receive a medication package on a monthly basis that consists of a monthly supply of berberine capsules or placebo capsules and one or two package of pills (letrozole or letrozole placebo, one package per month for the first three months, and two packages per month for the last three months). Berberine or berberine placebo will be administered orally at a daily dose of 1.5g for 6 months [26]. Patients will receive an initial dose of 2.5 mg (1 tablet) of letrozole or 1 tablet of letrozole placebo on days 3–7 of the first three treatment cycles and increased to 5 mg of letrozole (2 tablet) or 2 tablets of letrozole placebo on days 3–7 of the last three treatment cycles if not pregnant. Berberine and berberine placebo was produced by the Renhetang Pharmaceutical Co., Ltd., China. Letrozole and letrozole placebo were produced from Jiangsu Hengrui Medicine Co., Ltd., China.

2.4 Study specific visits and procedures

Each specific visit and measurement is summarized in Table 1. Baseline measures include fasting FSH, LH, total T, estradiol (E₂), glucose and insulin concentrations, cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and height, weight, hip, waist measurements, and vital signs. Also, TCM syndromes of each patient will be accessed with the aim to associate the TCM diagnosis to the study endpoint outcome on baseline visit. Syndrome differentiation in TCM is the

1
2
3 comprehensive analysis of clinical information gained by the four main diagnostic TCM
4 procedures: observation, listening, questioning, and pulse taking.²⁷ In PCOS, patients are
5 empirically differentiated to be four categories diagnosed by the local Chinese doctors : 1)
6 spleen deficiency and phlegm-dampness syndrome, 2) kidney deficiency and liver qi
7 stagnation syndrome, 3) kidney deficiency and blood stasis syndrome and 4) phlegm-
8 dampness and blood stasis syndrome.²⁸ The TCM diagnosis will be made by an experienced
9 TCM doctor in each participating site according to a standard questionnaire.
10
11
12
13
14
15
16
17
18

19 All baseline measures will be repeated in all subjects at the end of visits. Safety tests will be
20 repeated during monthly visit 3 and end of treatment visit. Blood samples will be collected
21 and shipped to the core laboratory.
22
23
24
25
26

27 **2.5 Randomization and Allocation concealment**

28
29 The randomization will be performed through a web-based randomization system
30 (<http://210.76.97.192:8080/cjbyj>) operated by an independent data center-Institute of Basic
31 Research In Clinical Medicine, China Academy of Chinese Medical Sciences (IBRCM).
32
33 Recruited subjects will be allocated randomly into one of the three groups in a ratio of 1:1:1.
34
35 The identification code and random number, which are unique for each participant, will be
36 given by a web-based system also produced by IBRCM. Subjects, investigators and
37 physicians taking care of subjects will be blinded to the assignment.
38
39
40
41
42
43
44

45 **2.6 Data Entry and Quality control of data**

46
47 Case Report Forms (CRFs) have been developed for data entry and an electronic version is
48 implemented in a Web-based data management system (<http://210.76.97.192:8080/cjbyj>).
49
50
51
52

53
54 Quality control of data will be handled at three different levels. The first level is the real-time
55 logical and range checking built into the web-based data entry system. The investigators at
56
57
58
59
60

1
2
3 the participating sites are required to ensure the data accuracy as the first defense. The
4
5 second is the remote data monitoring and validation that is the primary responsibility of the
6
7 study data manager and programmer. The data manager will conduct monthly
8
9 comprehensive data checks, as well as regular manual checks (within the database system).
10
11 Manual checks will identify more complicated and less common errors. The data manager
12
13 will query sites until each irregularity is resolved. The third level of quality control will be the
14
15 site visits, where data in our database will be compared against source documents.
16
17 Identified errors will be resolved between the data coordination center and clinical sites. The
18
19 visits will assure data quality and patient protection.
20
21

2.7 Sample size calculation and Statistical analysis

22
23

24 The sample size calculation is based on the live birth rate. The previous study showed that
25
26 the live birth rate of letrozole was 22%,²⁹ we hypothesis that combination of letrozole and
27
28 berberine can increase the life birth rate to 30%. According to the sample size of the
29
30 estimation formula³⁰
31

$$n = (u_{\alpha} + u_{\beta})^2 \times 2P \times (1 - P) / (P_0 - P_1)^2$$

32
33
34

35 It is estimated that a sample size of 220 subjects per group will be required, considering 20%
36
37 drop out. Intention-to-treat analysis will be applied to minimize bias due to dropouts.
38
39 Primary efficacy analysis will be done by comparing the treatment groups with respect to
40
41 the primary outcome of live birth using the Pearson Chi-square test.
42
43
44

45 For the secondary, supportive analysis, we will fit a logistic regression model to compare the
46
47 treatment arms with respect to the primary outcome of live birth, adjusting for other factors
48
49 such as randomization stratification of study site and prior exposure to study medications.
50
51 The analysis of other secondary outcomes measured over time will entail the application of
52
53 statistical methods that have been developed for correlated data since repeated
54
55 observations will be made over time on each individual. For secondary outcomes such as
56
57 hormone levels, a linear mixed-effects model will be fit where the main independent
58
59
60

1
2
3 variables will be treatment group, time, and their interaction as well as the designed
4 randomization stratification factors as covariates. Cox proportional hazards models and a
5 Kaplan-Meier method will be applied to compare time to pregnancy in the treatment groups.
6
7 Adverse events will be categorized and percentage of patients experiencing adverse events
8 and serious adverse events in this trial will be documented. Chi-square tests will be
9 performed to examine differences in the proportion of total and categories of adverse
10 events within each treatment arm. Unblinding of treatments will take place after all
11 participants have delivered or reported final outcomes or when there are medical
12 emergencies.
13
14
15
16
17
18
19

20 21 22 **3. Summary** 23 24

25
26 The present study has several distinctive features. To the best of our knowledge, this is the
27 first clinical trial assessing reproductive effects of berberine on women with PCOS using the
28 live birth rate as the primary outcome, instead of surrogate outcomes such as ovulation and
29 pregnancy rates or metabolic index such as insulin resistance and gluco-lipid profiles. The
30 present trial uses combination therapy of letrozole and berberine. Effects of berberine on
31 the ovulation, corpus lutein, implantation, obstetrics complications as well as teratogenic
32 effects at different stages of reproductive process will be assessed in the present study.
33 Compared with metformin, berberine has less and milder side effects and ameliorating
34 effects on lipid metabolism, which is also a stigma within women with PCOS.
35
36
37
38
39
40
41
42
43

44 **Author affiliations** 45

46
47 ¹Department of Obstetrics and Gynecology, National Key Discipline, Specialty and Clinical
48 Base, First Affiliated Hospital, Heilongjiang University of Chinese Medicine, 150040 Harbin,
49 China
50
51

52
53 ²Institute of Neuroscience and Physiology, Department of Physiology, Sahlgrenska Academy,
54 University of Gothenburg, 405 30 Gothenburg, Sweden
55
56
57
58
59
60

³ Department of Obstetrics and Gynecology, the University of Hong Kong, Queen Mary Hospital, Hong Kong Special Administrative Region, People's Republic of China

⁴ Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Bei San Huan Dong Lu 11, Chaoyang District, Beijing 100029, China.

⁵ School of Pharmacology, Heilongjiang University of Chinese Medicine, 150040 Harbin, China

*Correspondence should be addressed to Xiaoke Wu, xiaokewu2002@vip.sina.com and Lihui Hou, lihuihou2007@sina.com

Contributors WXK, HLH, LJP and LY developed the study protocol. LY, KHY, SWJ, MHL and ZYH coordinated the study. WXK and HLH will oversee enrolment and data collection. LY draft the manuscript in collaboration with ESV and EHYN. All authors have read and approved the final version of the manuscript.

Funding The study was funded by:

1. National Public Welfare Projects for Chinese Medicine (200807021)
2. Heilongjiang Province Foundation for Outstanding Youths (JC200804)
3. Intervention for Polycystic Ovary Syndrome Based on Traditional Chinese Medicine Theory- "TianGui Shi Xu" (2011TD006).

Competing interests None

Ethics approval The study was approved by the ethics committee of First Affiliated Hospital of Heilongjiang University of Chinese Medicine (2009LL-001-02).

Provenance and peer review Not commissioned; externally peer reviewed.

Reference

- [1] Norman RJ, Dewailly D, Legro RS, et al. Polycystic ovary syndrome, *Lancet* 2007; 370: 685-97
- [2] Pauli JM, Raja-Khan N, Wu X, et al. Current perspectives of insulin resistance and polycystic ovary syndrome, *Diabet Med* 2011; 28:1445-54
- [3] Dickey RP, Taylor SN, Curole DN, et al. Incidence of spontaneous abortion in clomiphene pregnancies. *Hum Reprod* 1996; 11:2623-28.
- [4] Gorbunov GA, Kase NG, Speroff L. Ovulation and pregnancy rates with clomiphene citrate. *Obstet Gynecol* 1978; 51:265-69.
- [5] Gysler M, March CM, Mishell DR Jr, et al. A decade's experience with an individualized clomiphene treatment regimen including its effects on the postcoital test. *Fertil Steril* 1982; 37:161-67.
- [6] Legro RS, Barnhart HX, Schlaff WD, et al.; Cooperative Multicenter Reproductive Medicine Network. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. *N Engl J Med* 2007; 356: 551-56, 2007
- [7] Gonen Y, Casper RF. Sonographic determination of an adverse effect of clomiphene citrate on endometrial growth. *Hum Reprod* 1990; 5:670-74.
- [8] Mitwally MF, Casper RF. Aromatase Inhibition: a novel method of ovulation induction in women with polycystic ovarian syndrome," *Reprod Technol* 2000; 10: 244-47.
- [9] Mitwally MF, Casper RF. Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. *Fertil Steril* 2001; 75: 305-09.
- [10] He D, Jiang F. Meta-analysis of letrozole versus clomiphene citrate in polycystic ovary syndrome. *Reprod Biomed Online* 2011; 23: 91-6
- [11] Misso ML, Wong JL, Teede HJ, et al. Aromatase inhibitors for PCOS: a systematic review and meta-analysis. *Hum Reprod Update* 2012; 18: 301-12.
- [12] Nahid L, Sirous K. Comparison of the effects of letrozole and clomiphene citrate for ovulation induction in infertile women with polycystic ovary syndrome. *Minerva Ginecol* 2012; 6:253-58.

- 1
2
3 [13] Legro RS, Kunselman AR, Brzyski RG, et al.; NICHD Reproductive Medicine
4 Network. NICHD Reproductive Medicine Network. The Pregnancy in Polycystic Ovary
5 Syndrome II (PPCOS II) trial: rationale and design of a double-blind randomized trial of
6 clomiphene citrate and letrozole for the treatment of infertility in women with polycystic
7 ovary syndrome. *Contemp Clin Trials* 2012; 33 :470-81.
- 8
9 [14] Diamond MP, Mitwally M, Casper R, et al.; NICHD Cooperative Reproductive Medicine
10 Network. Estimating rates of multiple gestation pregnancies: sample size calculation from
11 the Assessment of Multiple Intrauterine Gestations from Ovarian Stimulation (AMIGOS) trial.
12 *Contemp Clin Trials* 2011; 32:902-08.
- 13
14 [15] Tang T, Lord JM, Norman RJ, et al. Insulin-sensitising drugs (metformin, rosiglitazone,
15 pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome,
16 oligoamenorrhoea and subfertility. *Cochrane Database Syst Rev* 2012; 16: CD003053.
- 17
18 [16] Sinawat S, Buppasiri P, Lumbiganon P, et al. Long versus short course treatment with
19 metformin and clomiphene citrate for ovulation induction in women with PCOS. *Cochrane*
20 *Database Syst* 2012; 17: CD006226.
- 21
22 [17] Zhang J, Li T, Zhou L, et al. Chinese herbal medicine for subfertile women with polycystic
23 ovarian syndrome. *Cochrane Database Syst Rev* 2010; 8: CD007535.
- 24
25 [18] Birdsall TC, Kelly GS. Berberine: therapeutic potential of an alkaloid found in several
26 medicinal plants. *Alternative Med Rev* 1997; 2: 94-103.
- 27
28 [19] Dong H, Wang N, Zhao L, et al. Berberine in the treatment of type 2 diabetes mellitus: a
29 systemic review and meta-analysis. *Evid Based Complement Alternat Med* 2012; 2012: 591654.
- 30
31 [20] Kong W, Wei J, Abidi P, et al. Berberine is a novel cholesterol-lowering drug working
32 through a unique mechanism distinct from statins. *Nat Med* 2004; 10: 1344-51.
- 33
34 [21] Wu X. Theca insulin resistance: dexamethasone induction and berberine intervention,”
35 *Fertil Steril* 2010; 94: s197.
- 36
37 [22] Zhao L, Li W, Han F, et al. Berberine reduces insulin resistance induced by
38 dexamethasone in theca cells in vitro. *Fertil Steril* 2011; 95:461-63.
- 39
40 [23] Gao L, Li W, Kuang HY. Of berberine and puerarin on dexamethasone-induced insulin
41 resistance in porcine ovarian thecal cells. *ZhongGuo Zhong Xi Yi Jie He Za Zhi* 2009; 29: 623-
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 27.

5 [24] Wu XK, Yao JP, Hou LH, et al. Berberine improves insulin resistance in granulosa cells in
6 a similar way to metformin. *Fertil Steril* 2006; 86: 459-60.

7
8 [25] Wang XX, Li W, Liu YC. Controlling effect of berberine on in vitro synthesis and
9 metabolism of steroid hormones in insulin resistant ovary. *ZhongGuo Zhong Xi Yi Jie He Za*
10 *Zhi* 2010; 30: 161-66.

11 [26] Wei W, Zhao H, Wang A, et al. A clinical study on the short-term effect of berberine in
12 comparison to metformin on the metabolic characteristics of women with polycystic ovary
13 syndrome. *Eur J Endocrinol* 2012; 166: 99-105.

14 [27] Jiang M, Lu C, Zhang C, et al. Syndrome differentiation in modern research of traditional
15 Chinese medicine. *J Ethnopharmacol* 2012; 140: 634-42.

16 [28] Hou LH, Wang YT, Wu XK. *Today's gynecology of Chinese medicine (First edition)*.
17 People's Medical Publishing House 2011, ISBN 978-7-117-13644-0/R.13645.

18 [29] Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on
19 infertility treatment related to polycystic ovary syndrome. *Hum Reprod* 2008; 23:462-77.

20 [30] Liu JP. *Clinical research methodology for evidence-based Chinese medicine*, people's
21 medicine publishing house 2006; ISBN: 9787117074193.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Table 1. Overview of the study visits

	Screening Visit	Baseline Visit	Monthly Visit 1	Monthly Visit 2	Monthly Visit 3	Monthly Visit 4	Monthly Visit 5	End of Treatment Visit
Visit #	1	2	3	4	5	6	7	8
Sign Consent	x							
Urine Pregnancy Test	x		x	x	x	x	x	x
Physical Exam and History	x							x
Transvaginal Ultrasound	x				x			x
Semen Analysis	x							
Hysterosalpingogram or Sonohysterogram (SHG)	x							
Safety Eligibility Tests	x				x			x
Fasting Phlebotomy For Study Parameters		x			x			x
Progesterone Level			x	x	x	x	x	x
QoL Measures	x				x			x
Assess Adverse Events			x	x	x	x	x	x
Record Concomitant Meds	x	x	x	x	x	x	x	x



Letrozole, Berberine, or Their Combination for Anovulatory Infertility in women with Polycystic Ovary Syndrome: Study Design of a Double-blind Randomized Controlled Trial

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-003934.R1
Article Type:	Protocol
Date Submitted by the Author:	12-Oct-2013
Complete List of Authors:	Li, Yan; First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Obstetrics and Gynecology Kuang, Hongying; First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Obstetrics and Gynecology Shen, Wenjuan; First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Obstetrics and Gynecology Ma, Hongli; First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Obstetrics and Gynecology Zhang, Yuehui; First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Obstetrics and Gynecology Stener-Victorin, Elisabet; Institute of Neuroscience and Physiology, University of Gothenburg, Department of Physiology / Endocrinology Ng, Ernest; The University of Hong Kong, Obstetrics and Gynecology Liu, Jianping; Beijing University of Chinese Medicine, Centre for Evidence-Based Chinese Medicine Kuang, Haixue; Heilongjiang University of Chinese Medicine, School of Pharmacology Hou, Lihui; First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Obstetrics and Gynecology Xiao, Wu; First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Obstetrics and Gynecology
Primary Subject Heading:	Reproductive medicine
Secondary Subject Heading:	Diabetes and endocrinology, Complementary medicine, Reproductive medicine
Keywords:	REPRODUCTIVE MEDICINE, Protocols & guidelines < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Subfertility < GYNAECOLOGY, Herbal medicine < THERAPEUTICS, Clinical trials < THERAPEUTICS

1
2
3 **Letrozole, Berberine, or Their Combination for Anovulatory Infertility in women with**
4 **Polycystic Ovary Syndrome: Study Design of a Double-blind Randomized Controlled Trial**
5
6

7
8 Yan Li,¹ Hongying Kuang,¹ Wenjuan Shen,¹ Hongli Ma,¹ Yuehui Zhang,¹ Elisabet Stener-
9 Victorin,² Ernest Hung Yu Ng,³ Jianping Liu,⁴ Haixue Kuang⁵, Lihui Hou,^{1*} and Xiaoke Wu^{1*}
10
11

- 12 1. First Affiliated Hospital, Heilongjiang University of Chinese Medicine - Obstetrics and
13 Gynecology
14
- 15 2. Institute of Neuroscience and Physiology, University of Gothenburg - Department of
16 Physiology / Endocrinology
17
- 18 3. The University of Hong Kong - Obstetrics and Gynecology
19
- 20 4. Beijing University of Chinese Medicine - Centre for Evidence-Based Chinese Medicine
21
- 22 5. Heilongjiang University of Chinese Medicine - School of Pharmacology
23
24
25
26
27
28

29 **Keywords:** REPRODUCTIVE MEDICINE, Protocols & guidelines < HEALTH SERVICES ADMINISTRATION &
30 MANAGEMENT, Subfertility < GYNAECOLOGY, Herbal medicine < THERAPEUTICS, Clinical trials <
31 THERAPEUTICS
32
33

34
35 **Reference count:** 30
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Introduction: Letrozole is being used as an alternative to clomiphene citrate in women with polycystic ovary syndrome (PCOS) requiring ovulation induction. Berberine, a major active component of Chinese herbal medicine *rhizomacoptidis*, has been used to improve insulin resistance to facilitate ovulation induction in women with PCOS but there is no study reporting the live birth or its potential as an complementary treatment to letrozole. We here aim to determine the efficacy of letrozole with or without berberine in achieving live births among 660 infertile women with PCOS in Mainland China.

Methods and analysis: This study is a multicenter randomized, double blind trial. The randomization scheme is coordinated through the central mechanism and stratified by the participating site. Participants are randomized into one of three treatment arms: A) letrozole and berberine, B) letrozole and berberine placebo, or C) letrozole placebo and berberine. Berberine is administered three times a day (1.5g/day) for up to 24 weeks, starting on day 1 after a spontaneous period or a withdrawal bleeding. Either letrozole or letrozole placebo 2.5 mg is given daily from day 3 to day 7 of the first 3 cycles and the dose is increased to 5mg/day in the last 3 cycles, if not pregnant. The primary hypothesis is that combination of berberine and letrozole results in a significantly higher live birth rate than letrozole or berberine alone.

Ethics and dissemination: The study was approved by the ethics committee of First Affiliated Hospital of Heilongjiang University of Chinese Medicine. Study findings will be disseminated through peer-reviewed publications and conference presentations.

Trial registration: ClinicalTrials.gov identifier: NCT0116167

1. Background

Polycystic ovary syndrome (PCOS) is characterized by anovulation, hyperandrogenism and polycystic ovaries (PCO) on scanning and is the most common endocrine disorder in women of reproductive age as it affects 5-10% of premenopausal women.¹ Insulin resistance has been implicated in the pathogenesis of anovulation and infertility in PCOS and abnormalities in insulin action have been noted in a variety of reproductive tissues from women with PCOS and may explain the pleiotropic presentation and multi-organ involvement of the syndrome.²

The first line medical treatment for ovulation induction in PCOS women is clomiphene citrate (CC), which can result in an ovulation rate of 60–85% but a conception rate of only about 20%.³⁻⁶ Anti-oestrogenic effects on the endometrium and cervix mucus of CC are thought to cause the low conception rate.⁷ Also, CC may have a number of side effect including hot flushes, breast discomfort, abdominal distension, nausea, vomiting, nervousness, sleeplessness, headache, mood swings, dizziness, hair loss, and disturbed vision.⁶ Letrozole, an aromatase inhibitor, is traditionally applied for estrogen-dependent carcinoma, has been used for ovulation induction for about a decade.^{8,9} The effectiveness of letrozole versus CC for ovulation induction has been reviewed by two meta-analyses.^{10,11} In both meta-analyses that included six randomized controlled trials, it was concluded that even though letrozole was associated with a lower number of mature follicles per cycle, there was no significant difference in the ovulation rate per cycle or the pregnancy, multiple pregnancy or miscarriage rates between letrozole and CC. No difference was found in the live birth rate, although it was only assessed in one meta-analysis.¹¹

Based on the above two meta-analyses, letrozole appears to be at least as effective as CC in ovulation induction with some potential advantages over CC. Although side effects reported by patients in the group receiving CC were higher, while no complication was noted in the group receiving letrozole,¹² large sample sized clinical trials are still needed. As far as we know, two large randomized multicenter studies, PPCOSII (The Pregnancy in Polycystic

1
2
3 Ovary Syndrome II)¹³ and AMIGOS (Assessment of Multiple Intrauterine Gestations from
4 Ovarian Stimulation)¹⁴ are ongoing and can provide definitive evidence for pregnancy
5 outcome with the use of CC versus letrozole.
6
7
8

9
10
11 Insulin sensitizing agents are commonly used as adjunctive medication for women with
12 PCOS and metformin is widely chosen.¹⁵ Although a newly published meta-analysis showed
13 that there was no evidence that metformin improved live birth rates in combination with CC
14 (pooled OR 1.16, 95% CI 0.85 to 1.56, 7 trials, and 907 women), the clinical pregnancy rates
15 were higher for the combination of metformin and CC than CC alone (pooled OR 1.51, 95% CI
16 1.17 to 1.96, 11 trials, 1208 women).¹⁵ Further, metformin was associated with a higher
17 incidence of gastrointestinal disturbances than placebo (pooled OR 4.27, 95% CI 2.4 to 7.59, 5
18 trials, and 318 women), which hampered its clinical compliance with high dropout rates.¹⁶
19
20
21
22
23
24
25
26

27
28 Recent studies suggest that several Chinese herbal medicines could be beneficial as an
29 adjunct to conventional medical management of PCOS, but the evidence is limited due to
30 the poor methodology of existing trials.¹⁷ Berberine, the major active component of *rhizome*
31 *coptidis*, exists in a number of medicinal plants and displays a broad array of
32 pharmacological effects.¹⁸ In Chinese medicine, berberine has a long history for its anti-
33 diabetic effect. A recent meta-analysis compared different oral hypoglycaemics including
34 metformin, glipizide or rosiglitazone with berberine, and found no priority over glycaemic
35 control but a mild anti-dyslipidemic effect following berberine.¹⁹ The mechanism of its
36 hypolipidemic effect was studied using human hepatoma cells. Berberine acts differently
37 from that of statin drugs as it could up-regulate low-density lipoprotein receptor expression
38 independent of sterol regulatory element binding proteins, but dependent on extracellular
39 signal-regulated kinases (ERK) activation.²⁰
40
41
42
43
44
45
46
47
48
49
50

51
52 A series of basic research also implicated that berberine could have beneficial effects in
53 women with PCOS. In insulin resistant theca cells, berberine increased glucose transporter
54 (Glut)-4, decreased peroxisome proliferator-activated receptor (PPAR) - δ mRNA levels,
55
56
57
58
59
60

1
2
3 increased glucose uptake, and reduced insulin resistance.²¹⁻²³ These results indicate that
4
5 berberine can improve insulin sensitivity in insulin resistant ovary theca cells. In ovary
6
7 granulosa cell, berberine was found to reduce the ovarian estrogenic responsiveness by
8
9 their insulin sensitizing effects similar to metformin, but different from thiazolidinedione.²⁴
10
11 Berberine could also alleviate the degree of insulin resistance and the androgen synthesis in
12
13 cultured insulin resistant ovaries, indicating that berberine may have a favorable effect on
14
15 fertility in women with PCOS.²⁵
16

17
18 However, there is only one study investigating the effect of berberine in women with
19
20 PCOS.²⁶ Eighty-nine Chinese PCOS women with insulin resistance were randomized into one
21
22 of three treatment groups: berberine+ cyproterone acetate (CPA) (n=31), metformin +CPA
23
24 (n=30) and placebo +CPA (n=28) for three months. The author concluded that berberine
25
26 showed similar metabolic effects on amelioration of insulin sensitivity and reduction of
27
28 hyperandrogenemia, when compared to metformin. Berberine also appeared to have a
29
30 greater effect on the changes in body composition and dyslipidemia. That study was limited
31
32 by its small sample size, incomplete description of the methodology and use of surrogate
33
34 outcomes (anthropometric measures and hormonal and metabolic value changes). There is
35
36 also an ongoing trial (NCT01138930) testing efficacy of berberine on insulin resistance in
37
38 women with PCOS as measured by a hyperinsulinemic-euglycemic clamp. Berberine was
39
40 thought to be safe during clinical use.¹⁹ The side effects were commonly gastrointestinal
41
42 discomforts including constipation, diarrhea, nausea and abdominal distension. Constipation
43
44 was one of the most common gastrointestinal complaints, but it is predictable since
45
46 berberine had a long history used to treat diarrhea in China.
47

48
49 We aim to determine the efficacy of letrozole with or without berberine in achieving live
50
51 births among women with PCOS seeking pregnancy in China mainland. The primary
52
53 hypothesis is that combination of berberine and letrozole results in a significantly higher live
54
55 birth than letrozole or berberine alone. We report herein the study design of our ongoing
56
57 study.
58
59
60

2. Materials and methods

This is a multi-centre, randomized, double blind and controlled clinical trial. A total of 660 women with PCOS seeking pregnancy (or 220 per each treatment arm) will be enrolled at one of 18 participating sites and randomly assigned to three treatment arms.

The study was approved by the ethics committee of First Affiliated Hospital of Heilongjiang University of Chinese Medicine (2009LL-001-02). Written informed consent will be obtained from each patient prior her participation in the study. The trial is registered at clinicaltrials.gov (NCT01116167).

2.1. Primary and secondary outcomes

The primary outcome is that combination of berberine and letrozole results in a significantly higher live birth than letrozole or berberine alone.

Secondary outcomes are the adjunctive use of berberine to letrozole has an additive effect on the following:

- 1) Ovulation rate: Patients will take serum progesterone test at day 22 of each treatment cycle. Progesterone > 3 ng/mL will be considered as ovulation.
- 2) Ongoing pregnancy rate at around gestation 8-10 weeks. Pregnancy will be confirmed, if suspected, by measurement of serum hCG. Pregnancies will be followed by the serial rise of serum hCG and ultrasound will be utilized to determine location of the pregnancy and number of implantation sites. Participants who conceive will be followed through the study until the pregnancy has advanced to the point of determining the number of gestational sacs, their location, and fetal viability as determined by visualization of fetal heart motion by ultrasonography.
- 3) Multiple pregnancy rates.

- 1
- 2
- 3
- 4 4) Miscarriage rate: loss of an intrauterine pregnancy before 20 completed weeks of
- 5 gestation.
- 6
- 7 5) Other pregnancy complications such as early pregnancy loss, gestational diabetes
- 8 mellitus, pregnancy-induced hypertension and birth of small-for-gestational-age (SGA)
- 9 babies.
- 10
- 11 6) Infant outcome: We will review pregnancy and birth records to document neonatal
- 12 morbidity and mortality and the presence of fetal anomalies.
- 13
- 14 7) Changes in metabolic profile: Fasting glucose and insulin concentrations, cholesterol,
- 15 triglycerides, high-density lipoprotein (HDL-C) and low-density lipoprotein (LDL-C).
- 16 The blood sample for the tests will be draw at both the baseline visit and the end of
- 17 treatment visit.
- 18
- 19 8) Changes in hormonal profile: Follicle-stimulating hormone (FSH), Luteinizing
- 20 hormone (LH), total testosterone (T), Sex hormone-binding globulin (SHBG) and
- 21 Dehydroepiandrosterone sulfate (DHEAS). The fasting blood sample for the tests will
- 22 be draw at both the baseline visit and the end of treatment visit at menstrual cycle
- 23 day 3-7.
- 24
- 25 9) Side effect: The patient will asked to record adverse event and reported to the
- 26 coordinator during each visit.
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38

39 **2.2 Study population**

40
41
42 Women with PCOS who desire pregnancy are eligible if they fulfill the following criteria.

43 **2.2.1 Inclusion criteria**

- 44
- 45
- 46
- 47
- 48
- 49 1) Age between 20 and 40 years.
- 50
- 51 2) Confirmed diagnosis of PCOS according to the Rotterdam 2003 criteria (2 out of 3):
- 52
 - 53 a. Oligo- or anovulation
 - 54 b. Clinical and/or biochemical signs of hyperandrogenism
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- c. Polycystic ovaries and exclusion of other etiologies (congenital adrenal hyperplasia, androgen-secreting tumors, Cushing's syndrome)
 - 3) At least one patent tube and normal uterine cavity shown by hysterosalpingogram, HyCoSi or diagnostic laparoscopy within three years.
 - 4) Sperm concentration 15×10^6 /mL and progressive motility (grades a* and b**) $\geq 40\%$.
*Grade a: rapid progressive motility (sperm moving swiftly, usually in a straight line).
**Grade b: slow or sluggish progressive motility (sperm may be less linear in their progression).
 - 5) History of 1 year of infertility

2.2.2 Exclusion criteria

- 1) Use of hormonal drugs or other medications including Chinese herbal prescriptions in the past 3 months.
- 2) Patients with known severe organ dysfunction or mental illness.
- 3) Pregnancy, post-abortion or postpartum within the past 6 weeks.
- 4) Breastfeeding within the last 6 months.
- 5) Not willing to give written consent to the study.

Written informed consent will be obtained from each woman prior to the participation in this study.

2.3 Intervention

Eligible patients will be randomized into one of three arms: A) letrozole and berberine, B) letrozole and berberine placebo, C) letrozole placebo and berberine. Anovulatory patients will have a withdrawal bleed induced with a course of oral medroxyprogesterone acetate (MPA) before the initiation of study medication. Each subject will receive a medication package on a monthly basis that consists of a monthly supply of berberine capsules or placebo capsules and one or two package of pills (letrozole or letrozole placebo, one package per month for the first three months, and two packages per month for the last three months). Berberine or berberine placebo will be administered orally at a daily dose of

1
2
3 1.5g for 6 months [26]. Patients will receive an initial dose of 2.5 mg (1 tablet) of letrozole or
4 1 tablet of letrozole placebo on days 3–7 of the first three treatment cycles and increased to
5 5 mg of letrozole (2 tablet) or 2 tablets of letrozole placebo on days 3–7 of the last three
6
7
8 treatment cycles if not pregnant. Berberine and berberine placebo was produced by the
9 Renhetang Pharmaceutical Co., Ltd., China. Letrozole and letrozole placebo were produced
10 from Jiangsu Hengrui Medicine Co., Ltd., China.
11
12
13

14 15 16 **2.4 Study specific visits and procedures** 17

18 Each specific visit and measurement is summarized in Table 1. Baseline measures include
19 fasting FSH, LH, total T, estradiol (E₂), glucose and insulin concentrations, cholesterol,
20 triglycerides, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein
21 cholesterol (LDL-C) and height, weight, hip, waist measurements, and vital signs. Also, TCM
22 syndromes of each patient will be accessed with the aim to associate the TCM diagnosis to
23 the study endpoint outcome on baseline visit. Syndrome differentiation in TCM is the
24 comprehensive analysis of clinical information gained by the four main diagnostic TCM
25 procedures: observation, listening, questioning, and pulse taking.²⁷ In PCOS, patients are
26 empirically differentiated to be four categories diagnosed by the local Chinese doctors : 1)
27 spleen deficiency and phlegm-dampness syndrome, 2) kidney deficiency and liver qi
28 stagnation syndrome, 3) kidney deficiency and blood stasis syndrome and 4) phlegm-
29 dampness and blood stasis syndrome.²⁸ The TCM diagnosis will be made by an experienced
30 TCM doctor in each participating site according to a standard questionnaire.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45

46 All baseline measures will be repeated in all subjects at the end of visits. Safety tests will be
47 repeated during monthly visit 3 and end of treatment visit. Blood samples will be collected
48 and shipped to the core laboratory.
49
50
51

52 53 **2.5 Randomization and Allocation concealment** 54 55 56 57 58 59 60

1
2
3 The randomization will be performed through a web-based randomization system
4 (http://210.76.97.192:8080/cjbyj) operated by an independent data center-Institute of Basic
5 Research In Clinical Medicine, China Academy of Chinese Medical Sciences (IBRCM).
6
7 Recruited subjects will be allocated randomly into one of the three groups in a ratio of 1:1:1.
8
9 The identification code and random number, which are unique for each participant, will be
10 given by a web-based system also produced by IBRCM. Subjects, investigators and
11 physicians taking care of subjects will be blinded to the assignment.
12
13
14
15
16
17
18
19

20 **2.6 Data Entry and Quality control of data**

21 Case Report Forms (CRFs) have been developed for data entry and an electronic version is
22 implemented in a Web-based data management system (http://210.76.97.192:8080/cjbyj).
23
24
25
26
27

28 Quality control of data will be handled at three different levels. The first level is the real-time
29 logical and range checking built into the web-based data entry system. The investigators at
30 the participating sites are required to ensure the data accuracy as the first defense. The
31 second is the remote data monitoring and validation that is the primary responsibility of the
32 study data manager and programmer. The data manager will conduct monthly
33 comprehensive data checks, as well as regular manual checks (within the database system).
34 Manual checks will identify more complicated and less common errors. The data manager
35 will query sites until each irregularity is resolved. The third level of quality control will be the
36 site visits, where data in our database will be compared against source documents.
37 Identified errors will be resolved between the data coordination center and clinical sites. The
38 visits will assure data quality and patient protection.
39
40
41
42
43
44
45
46
47
48
49

50 **2.7 Participation timeline**

51 This trial was started on October 2009 and the first recruitment was on May 15th, 2010. The
52 intervention will take up to 6 months and patient will come to the hospital to see doctor at
53 least once a month to get progesterone test and medication.
54
55
56
57
58
59
60

2.8 Sample size calculation and Statistical analysis

The sample size calculation is based on the live birth rate. The previous study showed that the live birth rate of letrozole was 22%,²⁹ we hypothesis that combination of letrozole and berberine can increase the life birth rate to 30%. According to the sample size of the estimation formula³⁰

$$n = (u_{\alpha} + u_{\beta})^2 \times 2P \times (1 - P) / (P_0 - P_1)^2 \quad (\alpha = 0.05, \beta = 0.1)$$

It is estimated that a sample size of 220 subjects per group will be required, considering 20% drop out. Intention-to-treat analysis will be applied to minimize bias due to dropouts.

Primary efficacy analysis will be done by comparing the treatment groups with respect to the primary outcome of live birth using the Pearson Chi-square test.

For the secondary, supportive analysis, we will fit a logistic regression model to compare the treatment arms with respect to the primary outcome of live birth, adjusting for other factors such as randomization stratification of study site and prior exposure to study medications. The analysis of other secondary outcomes measured over time will entail the application of statistical methods that have been developed for correlated data since repeated observations will be made over time on each individual. For secondary outcomes such as hormone levels, a linear mixed-effects model will be fit where the main independent variables will be treatment group, time, and their interaction as well as the designed randomization stratification factors as covariates. Cox proportional hazards models and a Kaplan-Meier method will be applied to compare time to pregnancy in the treatment groups. Adverse events will be categorized and percentage of patients experiencing adverse events and serious adverse events in this trial will be documented. Chi-square tests will be performed to examine differences in the proportion of total and categories of adverse events within each treatment arm. Unblinding of treatments will take place after all participants have delivered or reported final outcomes or when there are medical emergencies.

3. Summary

The present study has several distinctive features. To the best of our knowledge, this is the first clinical trial assessing reproductive effects of berberine on women with PCOS using the live birth rate as the primary outcome, instead of surrogate outcomes such as ovulation and pregnancy rates or metabolic index such as insulin resistance and gluco-lipid profiles. The present trial uses combination therapy of letrozole and berberine. Effects of berberine on the ovulation, corpus lutein, implantation, and obstetrics complications as well as teratogenic effects at different stages of reproductive process will be assessed in the present study. Compared with metformin, berberine has less and milder side effects and ameliorating effects on lipid metabolism, which is also a stigma within women with PCOS.

Author affiliations

¹Department of Obstetrics and Gynecology, National Key Discipline, Specialty and Clinical Base, Heilongjiang University of Chinese Medicine, 150040 Harbin, China

² Institute of Neuroscience and Physiology, Department of Physiology, Sahlgrenska Academy, University of Gothenburg, 405 30 Gothenburg, Sweden

³ Department of Obstetrics and Gynecology, the University of Hong Kong, Queen Mary Hospital, Hong Kong Special Administrative Region, People's Republic of China

⁴ Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Bei San Huan Dong Lu 11, Chaoyang District, Beijing 100029, China.

⁵ School of Pharmacology, Heilongjiang University of Chinese Medicine, 150040 Harbin, China

*Correspondence should be addressed to Xiaoke Wu, xiaokewu2002@vip.sina.com and Lihui Hou, lihuihou2007@sina.com

1
2
3 **Contributors** W XK, HLH, LJP and LY developed the study protocol. LY, KHY, SWJ, MHL and
4
5 ZYH coordinated the study. W XK and HLH will oversee enrolment and data collection. LY
6
7 draft the manuscript in collaboration with ESV and EHYN. All authors have read and
8
9 approved the final version of the manuscript.
10

11
12
13 **Funding** The study was funded by:

- 14
15 1. National Public Welfare Projects for Chinese Medicine (200807021)
16
17 2. Heilongjiang Province Foundation for Outstanding Youths (JC200804)
18
19 3. Intervention for Polycystic Ovary Syndrome Based on Traditional Chinese Medicine
20
21 Theory- “TianGui Shi Xu” (2011TD006).
22
23

24 **Competing interests** None
25
26
27

28 **Ethics approval** The study was approved by the ethics committee of First Affiliated Hospital
29
30 of Heilongjiang University of Chinese Medicine (2009LL-001-02).
31
32

33 **Provenance and peer review** Not commissioned; externally peer reviewed.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Reference

- [1] Norman RJ, Dewailly D, Legro RS, et al. Polycystic ovary syndrome, *Lancet* 2007; 370: 685-97
- [2] Pauli JM, Raja-Khan N, Wu X, et al. Current perspectives of insulin resistance and polycystic ovary syndrome, *Diabet Med* 2011; 28:1445-54
- [3] Dickey RP, Taylor SN, Curole DN, et al. Incidence of spontaneous abortion in clomiphene pregnancies. *Hum Reprod* 1996; 11:2623-28.
- [4] Gorkitsky GA, Kase NG, Speroff L. Ovulation and pregnancy rates with clomiphene citrate. *Obstet Gynecol* 1978; 51:265-69.
- [5] Gysler M, March CM, Mishell DR Jr, et al. A decade's experience with an individualized clomiphene treatment regimen including its effects on the postcoital test. *Fertil Steril* 1982; 37:161-67.
- [6] Legro RS, Barnhart HX, Schlaff WD, et al.; Cooperative Multicenter Reproductive Medicine Network. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. *N Engl J Med* 2007; 356: 551-56, 2007
- [7] Gonen Y, Casper RF. Sonographic determination of an adverse effect of clomiphene citrate on endometrial growth. *Hum Reprod* 1990; 5:670-74.
- [8] Mitwally MF, Casper RF. Aromatase Inhibition: a novel method of ovulation induction in women with polycystic ovarian syndrome," *Reprod Technol* 2000; 10: 244-47.
- [9] Mitwally MF, Casper RF. Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. *Fertil Steril* 2001; 75: 305-09.
- [10] He D, Jiang F. Meta-analysis of letrozole versus clomiphene citrate in polycystic ovary syndrome. *Reprod Biomed Online* 2011; 23: 91-6
- [11] Misso ML, Wong JL, Teede HJ, et al. Aromatase inhibitors for PCOS: a systematic review and meta-analysis. *Hum Reprod Update* 2012; 18: 301-12.
- [12] Nahid L, Sirous K. Comparison of the effects of letrozole and clomiphene citrate for ovulation induction in infertile women with polycystic ovary syndrome. *Minerva Ginecol* 2012; 6:253-58.

- 1
2
3 [13] Legro RS, Kunselman AR, Brzyski RG, et al.; NICHD Reproductive Medicine
4 Network. NICHD Reproductive Medicine Network. The Pregnancy in Polycystic Ovary
5 Syndrome II (PPCOS II) trial: rationale and design of a double-blind randomized trial of
6 clomiphene citrate and letrozole for the treatment of infertility in women with polycystic
7 ovary syndrome. *Contemp Clin Trials* 2012; 33 :470-81.
- 8
9 [14] Diamond MP, Mitwally M, Casper R, et al.; NICHD Cooperative Reproductive Medicine
10 Network. Estimating rates of multiple gestation pregnancies: sample size calculation from
11 the Assessment of Multiple Intrauterine Gestations from Ovarian Stimulation (AMIGOS) trial.
12 *Contemp Clin Trials* 2011; 32:902-08.
- 13
14 [15] Tang T, Lord JM, Norman RJ, et al. Insulin-sensitising drugs (metformin, rosiglitazone,
15 pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome,
16 oligoamenorrhoea and subfertility. *Cochrane Database Syst Rev* 2012; 16: CD003053.
- 17
18 [16] Sinawat S, Buppasiri P, Lumbiganon P, et al. Long versus short course treatment with
19 metformin and clomiphene citrate for ovulation induction in women with PCOS. *Cochrane*
20 *Database Syst* 2012; 17: CD006226.
- 21
22 [17] Zhang J, Li T, Zhou L, et al. Chinese herbal medicine for subfertile women with polycystic
23 ovarian syndrome. *Cochrane Database Syst Rev* 2010; 8: CD007535.
- 24
25 [18] Birdsall TC, Kelly GS. Berberine: therapeutic potential of an alkaloid found in several
26 medicinal plants. *Alternative Med Rev* 1997; 2: 94-103.
- 27
28 [19] Dong H, Wang N, Zhao L, et al. Berberine in the treatment of type 2 diabetes mellitus: a
29 systemic review and meta-analysis. *Evid Based Complement Alternat Med* 2012; 2012: 591654.
- 30
31 [20] Kong W, Wei J, Abidi P, et al. Berberine is a novel cholesterol-lowering drug working
32 through a unique mechanism distinct from statins. *Nat Med* 2004; 10: 1344-51.
- 33
34 [21] Wu X. Theca insulin resistance: dexamethasone induction and berberine intervention,”
35 *Fertil Steril* 2010; 94: s197.
- 36
37 [22] Zhao L, Li W, Han F, et al. Berberine reduces insulin resistance induced by
38 dexamethasone in theca cells in vitro. *Fertil Steril* 2011; 95:461-63.
- 39
40 [23] Gao L, Li W, Kuang HY. Of berberine and puerarin on dexamethasone-induced insulin
41 resistance in porcine ovarian thecal cells. *ZhongGuo Zhong Xi Yi Jie He Za Zhi* 2009; 29: 623-
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

27.

[24] Wu XK, Yao JP, Hou LH, et al. Berberine improves insulin resistance in granulosa cells in a similar way to metformin. *Fertil Steril* 2006; 86: 459-60.

[25] Wang XX, Li W, Liu YC. Controlling effect of berberine on in vitro synthesis and metabolism of steroid hormones in insulin resistant ovary. *ZhongGuo Zhong Xi Yi Jie He Za Zhi* 2010; 30: 161-66.

[26] Wei W, Zhao H, Wang A, et al. A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. *Eur J Endocrinol* 2012; 166: 99-105.

[27] Jiang M, Lu C, Zhang C, et al. Syndrome differentiation in modern research of traditional Chinese medicine. *J Ethnopharmacol* 2012; 140: 634-42.

[28] Hou LH, Wang YT, Wu XK. *Today's gynecology of Chinese medicine (First edition)*. People's Medical Publishing House 2011, ISBN 978-7-117-13644-0/R.13645.

[29] Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. *Hum Reprod* 2008; 23:462-77.

[30] Liu JP. *Clinical research methodology for evidence-based Chinese medicine*, people's medicine publishing house 2006; ISBN: 9787117074193.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Table 1. Overview of the study visits

	Screening Visit	Baseline Visit	Monthly Visit 1	Monthly Visit 2	Monthly Visit 3	Monthly Visit 4	Monthly Visit 5	Monthly Visit 6	End of Treatment Visit
Visit #	1	2	3	4	5	6	7	8	9
Sign Consent	x								
Urine Pregnancy Test	x		x	x	x	x	x	x	x
Physical Exam and History	x								x
Transvaginal Ultrasound	x				x				x
Semen Analysis	x								
Hysterosalpingogram or Sonohysterogram (SHG)	x								
Safety Eligibility Tests	x				x				x
Fasting Phlebotomy For Study Parameters		x			x				x
Progesterone Level			x	x	x	x	x	x	x
QoL Measures	x				x				x
Assess Adverse Events			x	x	x	x	x	x	x
Record Concomitant Meds	x	x	x	x	x	x	x	x	x

Letrozole, Berberine, or Their Combination for Anovulatory Infertility in women with Polycystic Ovary Syndrome: Study Design of a Double-blind Randomized Controlled Trial

Yan Li,¹ Hongying Kuang,¹ Wenjuan Shen,¹ Hongli Ma,¹ Yuehui Zhang,¹ Elisabet Stener-Victorin,² Ernest Hung Yu Ng,³ Jianping Liu,⁴ Haixue Kuang⁵, Lihui Hou,^{1*} and Xiaoke Wu^{1*}

Abstract

Introduction: Letrozole is being used as an alternative to clomiphene citrate in women with polycystic ovary syndrome (PCOS) requiring ovulation induction. Berberine, a major active component of Chinese herbal medicine *rhizomacoptidis*, has been used to improve insulin resistance to facilitate ovulation induction in women with PCOS but there is no study reporting the live birth or its potential as an complementary treatment to letrozole. We here aim to determine the efficacy of letrozole with or without berberine in achieving live births among 660 infertile women with PCOS in Mainland China.

Methods and analysis: This study is a multicenter randomized, double blind trial. The randomization scheme is coordinated through the central mechanism and stratified by the participating site. Participants are randomized into one of three treatment arms: A) letrozole and berberine, B) letrozole and berberine placebo, or C) letrozole placebo and berberine. Berberine is administered three times a day (1.5g/day) for up to 24 weeks, starting on day 1 after a spontaneous period or a withdrawal bleeding. Either letrozole or letrozole placebo 2.5 mg is given daily from day 3 to day 7 of the first 3 cycles and the dose is increased to 5mg/day in the last 3 cycles, if not pregnant. The primary hypothesis is that combination of berberine and letrozole results in a significantly higher live birth rate than letrozole or berberine alone.

Ethics and dissemination: The study was approved by the ethics committee of First Affiliated Hospital of Heilongjiang University of Chinese Medicine. Study findings will be disseminated through peer-reviewed publications and conference presentations.

Trial registration: ClinicalTrials.gov identifier: [NCT01116167](https://clinicaltrials.gov/ct2/show/study/NCT01116167)

1. Background

Polycystic ovary syndrome (PCOS) is characterized by anovulation, hyperandrogenism and polycystic ovaries (PCO) on scanning and is the most common endocrine disorder in women of reproductive age as it affects 5-10% of premenopausal women.¹ Insulin resistance has been implicated in the pathogenesis of anovulation and infertility in PCOS and abnormalities in insulin action have been noted in a variety of reproductive tissues from women with PCOS and may explain the pleiotropic presentation and multi-organ involvement of the syndrome.²

The first line medical treatment for ovulation induction in PCOS women is clomiphene citrate (CC), which can result in an ovulation rate of 60–85% but a conception rate of only about 20%.³⁻⁶ Anti-oestrogenic effects on the endometrium and cervix mucus of CC are thought to cause the low conception rate.⁷ Also, CC may have a number of side effect including hot flushes, breast discomfort, abdominal distension, nausea, vomiting, nervousness, sleeplessness, headache, mood swings, dizziness, hair loss, and disturbed vision.⁶ Letrozole, an aromatase inhibitor, is traditionally applied for estrogen-dependent carcinoma, has been used for ovulation induction for about a decade.^{8,9} The effectiveness of letrozole versus CC for ovulation induction has been reviewed by two meta-analyses.^{10,11} In both meta-analyses that included six randomized controlled trials, it was concluded that even though letrozole was associated with a lower number of mature follicles per cycle, there was no significant difference in the ovulation rate per cycle or the pregnancy, multiple pregnancy or miscarriage rates between letrozole and CC. No difference was found in the live birth rate, although it was only assessed in one meta-analysis.¹¹

Based on the above two meta-analyses, letrozole appears to be at least as effective as CC in ovulation induction with some potential advantages over CC. Although side effects reported by patients in the group receiving CC were higher, while no complication was noted in the group receiving letrozole,¹² large sample sized clinical trials are still needed. As far as we know, two large randomized multicenter studies, PPCOSII (The Pregnancy in Polycystic

1
2
3 Ovary Syndrome II)¹³ and AMIGOS (Assessment of Multiple Intrauterine Gestations from
4 Ovarian Stimulation)¹⁴ are ongoing and can provide definitive evidence for pregnancy
5 outcome with the use of CC versus letrozole.
6
7
8
9

10
11 Insulin sensitizing agents are commonly used as adjunctive medication for women with
12 PCOS and metformin is widely chosen.¹⁵ Although a newly published meta-analysis showed
13 that there was no evidence that metformin improved live birth rates in combination with CC
14 (pooled OR 1.16, 95% CI 0.85 to 1.56, 7 trials, and 907 women), the clinical pregnancy rates
15 were higher for the combination of metformin and CC than CC alone (pooled OR 1.51, 95% CI
16 1.17 to 1.96, 11 trials, 1208 women).¹⁵ Further, metformin was associated with a higher
17 incidence of gastrointestinal disturbances than placebo (pooled OR 4.27, 95% CI 2.4 to 7.59, 5
18 trials, and 318 women), which hampered its clinical compliance with high dropout rates.¹⁶
19
20
21
22
23
24
25
26
27

28 Recent studies suggest that several Chinese herbal medicines could be beneficial as an
29 adjunct to conventional medical management of PCOS, but the evidence is limited due to
30 the poor methodology of existing trials.¹⁷ Berberine, the major active component of *rhizome*
31 *coptidis*, exists in a number of medicinal plants and displays a broad array of
32 pharmacological effects.¹⁸ In Chinese medicine, berberine has a long history for its anti-
33 diabetic effect. A recent meta-analysis compared different oral hypoglycaemics including
34 metformin, glipizide or rosiglitazone with berberine, and found no priority over glycaemic
35 control but a mild anti-dyslipidemic effect following berberine.¹⁹ The mechanism of its
36 hypolipidemic effect was studied using human hepatoma cells. Berberine acts differently
37 from that of statin drugs as it could up-regulate low-density lipoprotein receptor expression
38 independent of sterol regulatory element binding proteins, but dependent on extracellular
39 signal-regulated kinases (ERK) activation.²⁰
40
41
42
43
44
45
46
47
48
49
50

51
52 A series of basic research also implicated that berberine could have beneficial effects in
53 women with PCOS. In insulin resistant theca cells, berberine increased glucose transporter
54 (Glut)-4, decreased peroxisome proliferator-activated receptor (PPAR) - δ mRNA levels,
55
56
57
58
59
60

1
2
3 increased glucose uptake, and reduced insulin resistance.²¹⁻²³ These results indicate that
4
5 berberine can improve insulin sensitivity in insulin resistant ovary theca cells. In ovary
6
7 granulosa cell, berberine was found to reduce the ovarian estrogenic responsiveness by
8
9 their insulin sensitizing effects similar to metformin, but different from thiazolidinedione.²⁴
10
11 Berberine could also alleviate the degree of insulin resistance and the androgen synthesis in
12
13 cultured insulin resistant ovaries, indicating that berberine may have a favorable effect on
14
15 fertility in women with PCOS.²⁵
16

17
18 However, there is only one study investigating the effect of berberine in women with
19
20 PCOS.²⁶ Eighty-nine Chinese PCOS women with insulin resistance were randomized into one
21
22 of three treatment groups: berberine+ cyproterone acetate (CPA) (n=31), metformin +CPA
23
24 (n=30) and placebo +CPA (n=28) for three months. The author concluded that berberine
25
26 showed similar metabolic effects on amelioration of insulin sensitivity and reduction of
27
28 hyperandrogenemia, when compared to metformin. Berberine also appeared to have a
29
30 greater effect on the changes in body composition and dyslipidemia. That study was limited
31
32 by its small sample size, incomplete description of the methodology and use of surrogate
33
34 outcomes (anthropometric measures and hormonal and metabolic value changes). There is
35
36 also an ongoing trial (NCT01138930) testing efficacy of berberine on insulin resistance in
37
38 women with PCOS as measured by a hyperinsulinemic-euglycemic clamp. Berberine was
39
40 thought to be safe during clinical use.¹⁹ The side effects were commonly gastrointestinal
41
42 discomforts including constipation, diarrhea, nausea and abdominal distension. Constipation
43
44 was one of the most common gastrointestinal complaints, but it is predictable since
45
46 berberine had a long history used to treat diarrhea in China.
47

48
49 We aim to determine the efficacy of letrozole with or without berberine in achieving live
50
51 births among women with PCOS seeking pregnancy in China mainland. The primary
52
53 hypothesis is that combination of berberine and letrozole results in a significantly higher live
54
55 birth than letrozole or berberine alone. We report herein the study design of our ongoing
56
57 study.
58
59
60

2. Materials and methods

This is a multi-centre, randomized, double blind and controlled clinical trial. A total of 660 women with PCOS seeking pregnancy (or 220 per each treatment arm) will be enrolled at one of 18 participating sites and randomly assigned to three treatment arms.

The study was approved by the ethics committee of First Affiliated Hospital of Heilongjiang University of Chinese Medicine (2009LL-001-02). Written informed consent will be obtained from each patient prior her participation in the study. The trial is registered at clinicaltrials.gov (NCT01116167).

2.1. Primary and secondary outcomes

The primary outcome is that combination of berberine and letrozole results in a significantly higher live birth than letrozole or berberine alone.

Secondary outcomes are the adjunctive use of berberine to letrozole has an additive effect on the following:

- 1) Ovulation rate: Patients will take serum progesterone test at day 22 of each treatment cycle. Progesterone > 3 ng/mL will be considered as ovulation.
- 2) Ongoing pregnancy rate at around gestation 8-10 weeks. Pregnancy will be confirmed, if suspected, by measurement of serum hCG. Pregnancies will be followed by the serial rise of serum hCG and ultrasound will be utilized to determine location of the pregnancy and number of implantation sites. Participants who conceive will be followed through the study until the pregnancy has advanced to the point of determining the number of gestational sacs, their location, and fetal viability as determined by visualization of fetal heart motion by ultrasonography.
- 3) Multiple pregnancy rates.

- 1
- 2
- 3
- 4 4) Miscarriage rate: loss of an intrauterine pregnancy before 20 completed weeks of
- 5 gestation.
- 6
- 7 5) Other pregnancy complications such as early pregnancy loss, gestational diabetes
- 8 mellitus, pregnancy-induced hypertension and birth of small-for-gestational-age (SGA)
- 9 babies.
- 10
- 11 6) Infant outcome: We will review pregnancy and birth records to document neonatal
- 12 morbidity and mortality and the presence of fetal anomalies.
- 13
- 14 7) Changes in metabolic profile: Fasting glucose and insulin concentrations, cholesterol,
- 15 triglycerides, high-density lipoprotein (HDL-C) and low-density lipoprotein (LDL-C).
- 16 The blood sample for the tests will be draw at both the baseline visit and the end of
- 17 treatment visit.
- 18
- 19 8) Changes in hormonal profile: Follicle-stimulating hormone (FSH), Luteinizing
- 20 hormone (LH), total testosterone (T), Sex hormone-binding globulin (SHBG) and
- 21 Dehydroepiandrosterone sulfate (DHEAS). The fasting blood sample for the tests will
- 22 be draw at both the baseline visit and the end of treatment visit at menstrual cycle
- 23 day 3-7.
- 24
- 25 9) Side effect: The patient will asked to record adverse event and reported to the
- 26 coordinator during each visit.
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38

39 2.2 Study population

40 Women with PCOS who desire pregnancy are eligible if they fulfill the following criteria.

41 2.2.1 Inclusion criteria

- 42
- 43 1) Age between 20 and 40 years.
- 44
- 45 2) Confirmed diagnosis of PCOS according to the Rotterdam 2003 criteria (2 out of 3):
- 46
- 47 a. Oligo- or anovulation
- 48
- 49 b. Clinical and/or biochemical signs of hyperandrogenism
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
- c. Polycystic ovaries and exclusion of other etiologies (congenital adrenal hyperplasia, androgen-secreting tumors, Cushing's syndrome)
 - 3) At least one patent tube and normal uterine cavity shown by hysterosalpingogram, HyCoSi or diagnostic laparoscopy within three years.
 - 4) Sperm concentration 15×10^6 /mL and progressive motility (grades a* and b**) $\geq 40\%$.
*Grade a: rapid progressive motility (sperm moving swiftly, usually in a straight line).
**Grade b: slow or sluggish progressive motility (sperm may be less linear in their progression).
 - 5) History of 1 year of infertility

2.2.2 Exclusion criteria

- 22
23
24
25
26
27
28
29
30
31
32
33
34
35
- 1) Use of hormonal drugs or other medications including Chinese herbal prescriptions in the past 3 months.
 - 2) Patients with known severe organ dysfunction or mental illness.
 - 3) Pregnancy, post-abortion or postpartum within the past 6 weeks.
 - 4) Breastfeeding within the last 6 months.
 - 5) Not willing to give written consent to the study.

36
37
38
39

Written informed consent will be obtained from each woman prior to the participation in this study.

2.3 Intervention

40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Eligible patients will be randomized into one of three arms: A) letrozole and berberine, B) letrozole and berberine placebo, C) letrozole placebo and berberine. Anovulatory patients will have a withdrawal bleed induced with a course of oral medroxyprogesterone acetate (MPA) before the initiation of study medication. Each subject will receive a medication package on a monthly basis that consists of a monthly supply of berberine capsules or placebo capsules and one or two package of pills (letrozole or letrozole placebo, one package per month for the first three months, and two packages per month for the last three months). Berberine or berberine placebo will be administered orally at a daily dose of

1
2
3 1.5g for 6 months [26]. Patients will receive an initial dose of 2.5 mg (1 tablet) of letrozole or
4 1 tablet of letrozole placebo on days 3–7 of the first three treatment cycles and increased to
5 5 mg of letrozole (2 tablet) or 2 tablets of letrozole placebo on days 3–7 of the last three
6 treatment cycles if not pregnant. Berberine and berberine placebo was produced by the
7 Renhetang Pharmaceutical Co., Ltd., China. Letrozole and letrozole placebo were produced
8 from Jiangsu Hengrui Medicine Co., Ltd., China.

14 15 16 **2.4 Study specific visits and procedures**

17
18 Each specific visit and measurement is summarized in Table 1. Baseline measures include
19 fasting FSH, LH, total T, estradiol (E₂), glucose and insulin concentrations, cholesterol,
20 triglycerides, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein
21 cholesterol (LDL-C) and height, weight, hip, waist measurements, and vital signs. Also, TCM
22 syndromes of each patient will be accessed with the aim to associate the TCM diagnosis to
23 the study endpoint outcome on baseline visit. Syndrome differentiation in TCM is the
24 comprehensive analysis of clinical information gained by the four main diagnostic TCM
25 procedures: observation, listening, questioning, and pulse taking.²⁷ In PCOS, patients are
26 empirically differentiated to be four categories diagnosed by the local Chinese doctors : 1)
27 spleen deficiency and phlegm-dampness syndrome, 2) kidney deficiency and liver qi
28 stagnation syndrome, 3) kidney deficiency and blood stasis syndrome and 4) phlegm-
29 dampness and blood stasis syndrome.²⁸ The TCM diagnosis will be made by an experienced
30 TCM doctor in each participating site according to a standard questionnaire.

31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46 All baseline measures will be repeated in all subjects at the end of visits. Safety tests will be
47 repeated during monthly visit 3 and end of treatment visit. Blood samples will be collected
48 and shipped to the core laboratory.

51 52 53 **2.5 Randomization and Allocation concealment**

1
2
3 The randomization will be performed through a web-based randomization system
4 (http://210.76.97.192:8080/cjbyj) operated by an independent data center-Institute of Basic
5 Research In Clinical Medicine, China Academy of Chinese Medical Sciences (IBRCM).
6
7 Recruited subjects will be allocated randomly into one of the three groups in a ratio of 1:1:1.
8
9 The identification code and random number, which are unique for each participant, will be
10 given by a web-based system also produced by IBRCM. Subjects, investigators and
11
12 physicians taking care of subjects will be blinded to the assignment.
13
14
15
16
17
18
19

20 **2.6 Data Entry and Quality control of data**

21 Case Report Forms (CRFs) have been developed for data entry and an electronic version is
22 implemented in a Web-based data management system (http://210.76.97.192:8080/cjbyj).
23
24
25
26
27

28 Quality control of data will be handled at three different levels. The first level is the real-time
29 logical and range checking built into the web-based data entry system. The investigators at
30 the participating sites are required to ensure the data accuracy as the first defense. The
31 second is the remote data monitoring and validation that is the primary responsibility of the
32 study data manager and programmer. The data manager will conduct monthly
33 comprehensive data checks, as well as regular manual checks (within the database system).
34 Manual checks will identify more complicated and less common errors. The data manager
35 will query sites until each irregularity is resolved. The third level of quality control will be the
36 site visits, where data in our database will be compared against source documents.
37 Identified errors will be resolved between the data coordination center and clinical sites. The
38 visits will assure data quality and patient protection.
39
40
41
42
43
44
45
46
47
48
49

50 **2.7 Participation timeline**

51 This trial was started on October 2009 and the first recruitment was on May 15th, 2010. The
52 intervention will take up to 6 months and patient will come to the hospital to see doctor at
53 least once a month to get progesterone test and medication.
54
55
56
57
58
59
60

2.8 Sample size calculation and Statistical analysis

The sample size calculation is based on the live birth rate. The previous study showed that the live birth rate of letrozole was 22%,²⁹ we hypothesis that combination of letrozole and berberine can increase the life birth rate to 30%. According to the sample size of the estimation formula³⁰

$$n = (u_{\alpha} + u_{\beta})^2 \times 2P \times (1 - P) / (P_0 - P_1)^2 \quad (\alpha = 0.05, \beta = 0.1)$$

It is estimated that a sample size of 220 subjects per group will be required, considering 20% drop out. Intention-to-treat analysis will be applied to minimize bias due to dropouts.

Primary efficacy analysis will be done by comparing the treatment groups with respect to the primary outcome of live birth using the Pearson Chi-square test.

For the secondary, supportive analysis, we will fit a logistic regression model to compare the treatment arms with respect to the primary outcome of live birth, adjusting for other factors such as randomization stratification of study site and prior exposure to study medications. The analysis of other secondary outcomes measured over time will entail the application of statistical methods that have been developed for correlated data since repeated observations will be made over time on each individual. For secondary outcomes such as hormone levels, a linear mixed-effects model will be fit where the main independent variables will be treatment group, time, and their interaction as well as the designed randomization stratification factors as covariates. Cox proportional hazards models and a Kaplan-Meier method will be applied to compare time to pregnancy in the treatment groups. Adverse events will be categorized and percentage of patients experiencing adverse events and serious adverse events in this trial will be documented. Chi-square tests will be performed to examine differences in the proportion of total and categories of adverse events within each treatment arm. Unblinding of treatments will take place after all participants have delivered or reported final outcomes or when there are medical emergencies.

3. Summary

The present study has several distinctive features. To the best of our knowledge, this is the first clinical trial assessing reproductive effects of berberine on women with PCOS using the live birth rate as the primary outcome, instead of surrogate outcomes such as ovulation and pregnancy rates or metabolic index such as insulin resistance and gluco-lipid profiles. The present trial uses combination therapy of letrozole and berberine. Effects of berberine on the ovulation, corpus lutein, implantation, and obstetrics complications as well as teratogenic effects at different stages of reproductive process will be assessed in the present study. Compared with metformin, berberine has less and milder side effects and ameliorating effects on lipid metabolism, which is also a stigma within women with PCOS.

Author affiliations

¹Department of Obstetrics and Gynecology, National Key Discipline, Specialty and Clinical Base, Heilongjiang University of Chinese Medicine, 150040 Harbin, China

²Institute of Neuroscience and Physiology, Department of Physiology, Sahlgrenska Academy, University of Gothenburg, 405 30 Gothenburg, Sweden

³Department of Obstetrics and Gynecology, the University of Hong Kong, Queen Mary Hospital, Hong Kong Special Administrative Region, People's Republic of China

⁴Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Bei San Huan Dong Lu 11, Chaoyang District, Beijing 100029, China.

⁵School of Pharmacology, Heilongjiang University of Chinese Medicine, 150040 Harbin, China

*Correspondence should be addressed to Xiaoke Wu, xiaokewu2002@vip.sina.com and Lihui Hou, lihuihou2007@sina.com

1
2
3 **Contributors** W XK, HLH, LJP and LY developed the study protocol. LY, KHY, SWJ, MHL and
4
5 ZYH coordinated the study. W XK and HLH will oversee enrolment and data collection. LY
6
7 draft the manuscript in collaboration with ESV and EHYN. All authors have read and
8
9 approved the final version of the manuscript.
10

11
12
13 **Funding** The study was funded by:

- 14 1. National Public Welfare Projects for Chinese Medicine (200807021)
- 15 2. Heilongjiang Province Foundation for Outstanding Youths (JC200804)
- 16 3. Intervention for Polycystic Ovary Syndrome Based on Traditional Chinese Medicine
17 Theory- "TianGui Shi Xu" (2011TD006).
18
19
20
21
22
23

24 **Competing interests** None
25
26
27

28 **Ethics approval** The study was approved by the ethics committee of First Affiliated Hospital
29 of Heilongjiang University of Chinese Medicine (2009LL-001-02).
30
31
32

33 **Provenance and peer review** Not commissioned; externally peer reviewed.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Reference

- [1] Norman RJ, Dewailly D, Legro RS, et al. Polycystic ovary syndrome, *Lancet* 2007; 370: 685-97
- [2] Pauli JM, Raja-Khan N, Wu X, et al. Current perspectives of insulin resistance and polycystic ovary syndrome, *Diabet Med* 2011; 28:1445-54
- [3] Dickey RP, Taylor SN, Curole DN, et al. Incidence of spontaneous abortion in clomiphene pregnancies. *Hum Reprod* 1996; 11:2623-28.
- [4] Gorbunov GA, Kase NG, Speroff L. Ovulation and pregnancy rates with clomiphene citrate. *Obstet Gynecol* 1978; 51:265-69.
- [5] Gysler M, March CM, Mishell DR Jr, et al. A decade's experience with an individualized clomiphene treatment regimen including its effects on the postcoital test. *Fertil Steril* 1982; 37:161-67.
- [6] Legro RS, Barnhart HX, Schlaff WD, et al.; Cooperative Multicenter Reproductive Medicine Network. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. *N Engl J Med* 2007; 356: 551-56, 2007
- [7] Gonen Y, Casper RF. Sonographic determination of an adverse effect of clomiphene citrate on endometrial growth. *Hum Reprod* 1990; 5:670-74.
- [8] Mitwally MF, Casper RF. Aromatase Inhibition: a novel method of ovulation induction in women with polycystic ovarian syndrome," *Reprod Technol* 2000; 10: 244-47.
- [9] Mitwally MF, Casper RF. Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. *Fertil Steril* 2001; 75: 305-09.
- [10] He D, Jiang F. Meta-analysis of letrozole versus clomiphene citrate in polycystic ovary syndrome. *Reprod Biomed Online* 2011; 23: 91-6
- [11] Misso ML, Wong JL, Teede HJ, et al. Aromatase inhibitors for PCOS: a systematic review and meta-analysis. *Hum Reprod Update* 2012; 18: 301-12.
- [12] Nahid L, Sirous K. Comparison of the effects of letrozole and clomiphene citrate for ovulation induction in infertile women with polycystic ovary syndrome. *Minerva Ginecol* 2012; 6:253-58.

- 1
2
3 [13] Legro RS, Kunselman AR, Brzyski RG, et al.; NICHD Reproductive Medicine
4 Network. NICHD Reproductive Medicine Network. The Pregnancy in Polycystic Ovary
5 Syndrome II (PPCOS II) trial: rationale and design of a double-blind randomized trial of
6 clomiphene citrate and letrozole for the treatment of infertility in women with polycystic
7 ovary syndrome. *Contemp Clin Trials* 2012; 33 :470-81.
- 8
9 [14] Diamond MP, Mitwally M, Casper R, et al.; NICHD Cooperative Reproductive Medicine
10 Network. Estimating rates of multiple gestation pregnancies: sample size calculation from
11 the Assessment of Multiple Intrauterine Gestations from Ovarian Stimulation (AMIGOS) trial.
12 *Contemp Clin Trials* 2011; 32:902-08.
- 13
14 [15] Tang T, Lord JM, Norman RJ, et al. Insulin-sensitising drugs (metformin, rosiglitazone,
15 pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome,
16 oligoamenorrhoea and subfertility. *Cochrane Database Syst Rev* 2012; 16: CD003053.
- 17
18 [16] Sinawat S, Buppasiri P, Lumbiganon P, et al. Long versus short course treatment with
19 metformin and clomiphene citrate for ovulation induction in women with PCOS. *Cochrane*
20 *Database Syst* 2012; 17: CD006226.
- 21
22 [17] Zhang J, Li T, Zhou L, et al. Chinese herbal medicine for subfertile women with polycystic
23 ovarian syndrome. *Cochrane Database Syst Rev* 2010; 8: CD007535.
- 24
25 [18] Birdsall TC, Kelly GS. Berberine: therapeutic potential of an alkaloid found in several
26 medicinal plants. *Alternative Med Rev* 1997; 2: 94-103.
- 27
28 [19] Dong H, Wang N, Zhao L, et al. Berberine in the treatment of type 2 diabetes mellitus: a
29 systemic review and meta-analysis. *Evid Based Complement Alternat Med* 2012; 2012: 591654.
- 30
31 [20] Kong W, Wei J, Abidi P, et al. Berberine is a novel cholesterol-lowering drug working
32 through a unique mechanism distinct from statins. *Nat Med* 2004; 10: 1344-51.
- 33
34 [21] Wu X. Theca insulin resistance: dexamethasone induction and berberine intervention,”
35 *Fertil Steril* 2010; 94: s197.
- 36
37 [22] Zhao L, Li W, Han F, et al. Berberine reduces insulin resistance induced by
38 dexamethasone in theca cells in vitro. *Fertil Steril* 2011; 95:461-63.
- 39
40 [23] Gao L, Li W, Kuang HY. Of berberine and puerarin on dexamethasone-induced insulin
41 resistance in porcine ovarian thecal cells. *ZhongGuo Zhong Xi Yi Jie He Za Zhi* 2009; 29: 623-
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 27.

5 [24] Wu XK, Yao JP, Hou LH, et al. Berberine improves insulin resistance in granulosa cells in
6 a similar way to metformin. *Fertil Steril* 2006; 86: 459-60.

7
8 [25] Wang XX, Li W, Liu YC. Controlling effect of berberine on in vitro synthesis and
9 metabolism of steroid hormones in insulin resistant ovary. *ZhongGuo Zhong Xi Yi Jie He Za*
10 *Zhi* 2010; 30: 161-66.

11
12 [26] Wei W, Zhao H, Wang A, et al. A clinical study on the short-term effect of berberine in
13 comparison to metformin on the metabolic characteristics of women with polycystic ovary
14 syndrome. *Eur J Endocrinol* 2012; 166: 99-105.

15
16 [27] Jiang M, Lu C, Zhang C, et al. Syndrome differentiation in modern research of traditional
17 Chinese medicine. *J Ethnopharmacol* 2012; 140: 634-42.

18
19 [28] Hou LH, Wang YT, Wu XK. *Today's gynecology of Chinese medicine (First edition)*.
20 People's Medical Publishing House 2011, ISBN 978-7-117-13644-0/R.13645.

21
22 [29] Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on
23 infertility treatment related to polycystic ovary syndrome. *Hum Reprod* 2008; 23:462-77.

24
25 [30] Liu JP. *Clinical research methodology for evidence-based Chinese medicine*, people's
26 medicine publishing house 2006; ISBN: 9787117074193.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Table 1. Overview of the study visits

	Screening Visit	Baseline Visit	Monthly Visit 1	Monthly Visit 2	Monthly Visit 3	Monthly Visit 4	Monthly Visit 5	Monthly Visit 6	End of Treatment Visit
Visit #	1	2	3	4	5	6	7	8	9
Sign Consent	x								
Urine Pregnancy Test	x		x	x	x	x	x	x	x
Physical Exam and History	x								x
Transvaginal Ultrasound	x				x				x
Semen Analysis	x								
Hysterosalpingogram or Sonohysterogram (SHG)	x								
Safety Eligibility Tests	x				x				x
Fasting Phlebotomy For Study Parameters		x			x				x
Progesterone Level			x	x	x	x	x	x	x
QoL Measures	x				x				x
Assess Adverse Events			x	x	x	x	x	x	x
Record Concomitant Meds	x	x	x	x	x	x	x	x	x